New stock news | Aikebaifa submits documents to Hong Kong Stock Exchange three times

06:20 18/03/2026

According to the disclosure by the Hong Kong Stock Exchange on March 17, Shanghai Aikabai Bio-Pharmaceutical Technology Co., Ltd.-B (referred to as Aikabai) has submitted its listing application to the main board of the Hong Kong Stock Exchange, with CITIC Securities and J.P. Morgan serving as its joint sponsors.

According to the disclosure made by the Hong Kong Stock Exchange on March 17th, Shanghai Aikang Pharmaceuticals Technology Co., Ltd. - B (referred to as Aikang Pharmaceuticals) has submitted its listing application to the Hong Kong Stock Exchange. CITIC SEC and J.P. Morgan are its joint sponsors. This is the third time the company has submitted documents to the Hong Kong Stock Exchange. According to the prospectus, Aikang Pharmaceuticals is a biopharmaceutical company established in 2013, focusing on the discovery and development of therapies to address medical needs in the respiratory and pediatric diseases. Aikang Pharmaceuticals has developed a pipeline of six candidate drugs, including two core products, namely (i) Cerevesofer, a respiratory syncytial virus (RSV) drug; and (ii) AK3280, a drug for idiopathic pulmonary fibrosis (IPF) in the concept verification stage after phase II.

HK Stock Market Move | YADEA(01585) rose over 13% in early trading, and is expected to make a net profit of over 2.9 billion yuan last year. The market anticipates that under high oil prices, electric motorcycles will have an opportunity.

CHINA TIANRUI (01252) will be temporarily suspended from trading starting from the morning of March 23, reasons to be announced.

Focusing on "The 15th Five-Year Plan", AI + finance is becoming a driving force for promoting consumption and infrastructure construction. QiFu Technology was invited to attend the China Development High-Level Forum.

CHINA TIANRUI (01252) will be temporarily suspended from trading starting from the morning of March 23, reasons to be announced.